TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00068484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03074318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Given IV
Study: NCT03991468

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Slide Imaging
Description: Scanning of a glass slide to create a digital image that can be viewed on a monitor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Light Microscopy
Description: Use of traditional light microscopy per institutional standard practice
Study: NCT03385434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorings-2
Description: 292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
Study: NCT02428075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
Study: NCT02177214

Intervention type: PROCEDURE
Intervention: MRI scan
Description: Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
Study: NCT03177174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: radiotherapy combined with Chemotherapy Drugs, Cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: radiotherapy combined with Chemotherapy Drugs, Cancer
Study: NCT00731952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade and Vorinostat
Description: Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
Study: NCT00691977

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy followed by prostatectomy
Description: Radiation Therapy
Study: NCT00645203

Intervention type: DRUG
Group type: OTHER
Intervention: cefdinir
Description: cefdinir oral suspension, 25 mg/kg once daily for 10 days
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
Study: NCT04616794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Engagement Group
Description: Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Group
Description: Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Group
Description: Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal group
Description: Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
Study: NCT02915692

Intervention type: DEVICE
Intervention: ERASE Silver Coated Foley Catheter
Description: Foley catheter from ERASE CAUTI Kit will be administered as required.

Intervention type: DEVICE
Intervention: Comparator Silver Coated Catheter
Description: Foley catheter coated with silver
Study: NCT02636738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vela XL thulium laser, laser fiber and accessories.
Description: The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
Study: NCT02905110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir
Description: Surgical catheter placement into the fourth ventricle of the brain
Study: NCT04298749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 1)
Description: GX-P1 dose level 1 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 2)
Description: GX-P1 dose level 2 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 3)
Description: GX-P1 dose level 3 or placebo
Study: NCT03382327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical planning
Description: Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
Study: NCT03365440

Intervention type: DEVICE
Intervention: esoECG-3D catheter
Description: Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.

Intervention type: DEVICE
Intervention: esoECG-3D catheter
Description: Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.

Intervention type: DEVICE
Intervention: esoECG-3D catheter
Description: Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
Study: NCT01333462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Study: NCT03498989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preterm formula milk
Description: A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exclusive breast milk
Description: exclusive breast milk
Study: NCT00810251

Intervention type: DEVICE
Intervention: MatrixRIB (FDA Approval # K081623)
Description: MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
Study: NCT00763178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose
Study: NCT01355497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subject will receive matching placebo for the duration of the trial
Study: NCT04673461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA363 containing 90 mg (60 mg/mL) lactic acid
Description: STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA363 containing 180 mg (120 mg/mL) lactic acid
Description: STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
Study: NCT04142944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 with alert
Description: Dexcom G6 CGM device with the predictive hypoglycaemia alert function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6 without alert
Description: Dexcom G6 CGM device without the predictive hypoglycaemia alert function
Study: NCT03225651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear cells

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological therapy and Rehabilitation
Description: Psychological Therapy and Rehabilitation for autism children around 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological therapy and Rehabilitation
Description: Psychological Therapy and Rehabilitation for autism children around 3 months
Study: NCT04157751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Empagliflozin
Description: Film-coated tablet
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Study: NCT05125991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prepectoral reconstruction
Description: Prepectoral breast reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submuscolar reconstruction
Description: Submuscolar breast reconstruction
Study: NCT01929512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 750/20mg
Description: 750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 750/20mg
Description: 750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 750mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 750mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Study: NCT01581996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanthanum carbonate
Description: All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
Study: NCT00671970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib
Description: Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
Study: NCT03177174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study: NCT04663295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 670G system
Description: Hybrid closed loop insulin pump with associated CGM and blood glucose meter
Study: NCT04242914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
Study: NCT03275064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 intra-articular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 intra-articular injection
Study: NCT03094494

Intervention type: OTHER
Intervention: none intervention
Description: none intervention

Intervention type: OTHER
Intervention: none intervention
Description: none intervention
Study: NCT01429155

Intervention type: GENETIC
Intervention: Interleukin 28B genotype
Description: Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Intervention type: GENETIC
Intervention: Interleukin 28B genotype
Description: Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
Study: NCT01456520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vycavert
Description: single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
Study: NCT04557007

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Study: NCT03084432

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorptiometry
Description: Dual Energy X-ray Absorptiometry done for both studied groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorptiometry
Description: Dual Energy X-ray Absorptiometry done for both studied groups
Study: NCT03650036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Therapy CTZ Paste
Description: CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Therapy ZOE Paste
Description: The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
Study: NCT02826655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WF-AO-OCT
Description: WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WF-AO-OCT
Description: WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
Study: NCT03632668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2071 10/20mg
Description: AD-2071 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2072 80/5mg
Description: AD-2072 80/5mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2071 10/20mg + AD2072 80/5mg
Description: AD-2071 10/20 mg + AD-2072 80/5mg tablet
Study: NCT04489940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Study: NCT02352350

Intervention type: OTHER
Intervention: Blood Lactate Levels
Description: Blood lactate levels will be performed on all participants.

Intervention type: OTHER
Intervention: Neurological Outcomes
Description: Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.